TOVX
Theriva Biologics, Inc.
NYSE · Healthcare
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | ||||||||||||||||
| Operating Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amort. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Comp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Changes in WC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing | ||||||||||||||||
| Capital Expenditures | 35,000 | 1,000 | 202,000 | 116,000 | 14,000 | 9,000 | 0 | 7,000 | 212,000 | 569,000 | 501,000 | 48,000 | 36,000 | 10,000 | 0 | 12,000 |
| Acquisitions | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing | ||||||||||||||||
| Debt Repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Common Stock Issued | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Summary | ||||||||||||||||
| Free Cash Flow | -16.7M | -16.9M | -19.2M | -19.2M | -12.9M | -12.2M | -13.9M | -17.3M | -20.4M | -28.5M | -39.4M | -16.1M | -7.8M | -8.9M | -2.9M | -1.2M |
| Net Change in Cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |